Ainos, Inc. (NASDAQ:AIMD) Short Interest Update

Ainos, Inc. (NASDAQ:AIMD) saw a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 143,300 shares, a decrease of 40.0% from the October 15th total of 238,800 shares. Currently, 5.7% of the company’s stock are sold short. Based on an average trading volume of 656,000 shares, the short-interest ratio is presently 0.2 days.

Ainos Price Performance

NASDAQ AIMD opened at $0.50 on Wednesday. The firm’s fifty day simple moving average is $0.51 and its two-hundred day simple moving average is $0.72. The company has a quick ratio of 1.45, a current ratio of 1.37 and a debt-to-equity ratio of 0.50. Ainos has a 12-month low of $0.40 and a 12-month high of $4.29.

Ainos (NASDAQ:AIMD) last announced its earnings results on Wednesday, November 6th. The company reported ($0.33) earnings per share for the quarter. Ainos had a negative return on equity of 75.16% and a negative net margin of 15,348.14%.

Ainos Company Profile

Ainos, Inc, a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan.